Express Mail Label No.	Dated:
6.7	
81	

Docket No.: 02755/100J533-US1

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Bruce E. Reidenberg et al.

Application No.: 10/736,043

Confirmation No.: 4015

Filed: December 15, 2003

Art Unit: 1615

For:

TRANSDERMAL BUPREORPHINE

Examiner: Not Yet Assigned

DOSAGE REGIMEN FOR ANALGESIA

## SECOND INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each document on the PTO/SB/08 is attached.

Application No.: 10/736,043 2 Docket No.: 02755/100J533-US1

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: April 21, 2004

Respectfully submitted,

Anna Lövqvist, Ph.D.

Limited Recognition Under 37 C.F.R. 10.9(b) (see attached)

Representative of Applicants

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 753-6237 (Fax)

Attorneys/Agents For Applicant

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/B/PTO 10/736,043 Application Number · INFORMATION DISCLOSURE Filing Date December 15, 2003 STATEMENT BY APPLICANT First Named Inventor Bruce E. Reidenberg Art Unit (Use as many sheets as necessary) Examiner Name Not Yet Assigned 02755/100J533-US1 Sheet 1 Attorney Docket Number

U.S. PATENT DOCUMENTS					
Examiner Cite Initials* No.1	Cito	Document Number	Publication Date MM-DD-YYYY	Traine or Faternee or	Pages, Columns, Lines, Where
		Number-Kind Code <sup>2</sup> ( if known)			Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Date MM-DD-YYYY	Date Applicant of Cited Decument		T <sup>6</sup>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language

NON PATENT LITERATURE DOCUMENTS					
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the article (when appropri					
	CA	Ahmedzai, Eur. J. Cancer 1997;33:58-514			
	СВ	Bentley et al., Anesth Anal 1982;61:968-971			
	CC	Cathelin et al., Anesth Anal (Paris). 1980;37(5-6):283-93			
	CD	Dayer et al., Drugs 1997;53:18-24			
	CE	Holdsworth et al., Gerontology 1994;40:32-37			
	CF	Jeal and Benfield, Drugs 1997;53:109-138	Ī		
	CG	Melon et al., Anesth Anal Rean 1980;37:121-125	Γ		
	СН	Mercandente, Cancer 1999;86:1856-66			
	CI	Mercadente and Fulfaro, Oncology 1999;13:215-220, 225			
	CJ	Thompson et al., Br J Anaesth 1998;81:152-154			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	 Date	
Signature	Considered	
Olgitature	Considered	1

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.